2M.D., Special Megapark Hospital, Eye Clinic, Kahramanmaras/TURKEY
3M.D., Special Megapark Hospital, Neonatology Clinic, Kahramanmaras/TURKEY Purpose: To purpose of this study is to evaluate the outcomes of intravitreal bevacizumab injection for a specific subgroup of ROP cases with immature macula.
Materials and Methods: ROP cases with immature macula who needed treatment were included. Twentyfive eyes of 14 patients received 0.5 mg/0.02 ml bevacizumab intravitreally from June 2011 to February 2012. Informed consent was obtained from all families.
Results: Mean gestational age was 29 weeks (26-31 weeks). Mean gestational age at the time of injection was 35 weeks (32- 37 weeks). Mean follow-up time was 7 months. Twelve eyes had zone I plus disease, 8 eyes had zone I neovascularization and 5 eyes had zone II stage 3 with plus disease. Macula was immature with incomplete vascularization in all eyes. One patient died of systemic infection at week 60. Two eyes needed additional laser photocoagulation. ROP regressed in 17 eyes without further treatment and development of normal retinal vascularization was observed during the follow-up period.
Conclusion: Intravitreal bevacizumab injection for selected cases of ROP is an effective treatment regiment. Ocular and systemic complications should be evaluated with long term clinical studies.
Keywords : Intravitreal bevacizumab, retinopathy of prematurity, aggressive posterior disease